12/16
08:06 am
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
12/16
06:20 am
carm
Carisma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Medium
Report
Carisma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
12/16
06:20 am
carm
Carisma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Medium
Report
Carisma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
12/12
08:07 am
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $10.00.
Medium
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $10.00.
12/12
05:49 am
carm
Rating for CARM
High
Report
Rating for CARM
12/12
05:49 am
carm
Rating for CARM
High
Report
Rating for CARM
12/12
05:03 am
carm
Carisma Therapeutics downgraded to Neutral from Outperform at Baird
Medium
Report
Carisma Therapeutics downgraded to Neutral from Outperform at Baird
12/12
05:03 am
carm
Carisma Therapeutics downgraded to Neutral from Outperform at Baird
Medium
Report
Carisma Therapeutics downgraded to Neutral from Outperform at Baird
12/11
12:29 pm
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $0.70 price target on the stock, down previously from $4.00.
Medium
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $0.70 price target on the stock, down previously from $4.00.
12/11
12:29 pm
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $0.70 price target on the stock, down previously from $4.00.
Medium
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $0.70 price target on the stock, down previously from $4.00.
12/11
12:17 pm
carm
Rating for CARM
High
Report
Rating for CARM
12/11
08:58 am
carm
Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI
High
Report
Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI
12/11
08:58 am
carm
Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI
High
Report
Carisma Therapeutics downgraded to In Line from Outperform at Evercore ISI
12/10
12:51 pm
carm
Rating for CARM
Low
Report
Rating for CARM
12/10
08:08 am
carm
Carisma Therapeutics, Inc. (NASDAQ: CARM) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
High
Report
Carisma Therapeutics, Inc. (NASDAQ: CARM) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.
12/9
04:20 pm
carm
Carisma Therapeutics downgraded to Neutral from Buy at BTIG
High
Report
Carisma Therapeutics downgraded to Neutral from Buy at BTIG